Results 261 to 270 of about 128,640 (296)
Some of the next articles are maybe not open access.
Glucagon-like Peptide-1 Receptor Agonists
2021Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) have been used to treat patients with type 2 diabetes mellitus (T2DM) since exenatide, the first GLP-1RA, was approved in 2005. GLP-1 is a peptide hormone secreted by L cells of the small intestine in response to nutrients.
Ja Young Jeon, Hae Jin Kim
openaire +1 more source
The discovery of glucagon-like peptide 1
Regulatory Peptides, 2005The discovery of glucagon-like peptide 1 (GLP-1) began more than two decades ago with the observations that anglerfish islet proglucagon messenger RNAs (mRNAs) contained coding sequences for two glucagon-related peptides arranged in tandem. Subsequent analyses revealed that mammalian proglucagon mRNAs encoded a precursor containing the sequence of ...
openaire +2 more sources
Glucagon-like Peptide-1 Receptor-based Therapeutics for Metabolic Liver Disease
Endocrine Reviews, 2023Daniel J Drucker
exaly
[Glucagon-like peptide-1 receptor agonists].
Nihon rinsho. Japanese journal of clinical medicine, 2015Recently, the number of diabetic patients with obesity has increased by changes in life-style including food and physical exercise. Appearance of incretin-related drugs has given us more options for treating type 2 diabetes, and they are evaluated in regard to realizing appropriately controlled glycemic status.
Yamato, Mashimo, Kazuhiro, Eto
openaire +1 more source
Glucagon-like peptide 1 receptor
AfCS-Nature Molecule Pages, 2005Dieter Hoersch +2 more
openaire +1 more source
[Glucagon-like peptide 1 (GLP-1)].
MMW Fortschritte der Medizin, 2007GLP-1 receptor agonists such as exenatide are a group of new therapeutic agents that mimic the gut-derived incretin hormone GLP-1. These drugs stimulate insulin secretion while suppressing glucagon secretion, inhibit gastric motility, reduce appetite and hence, food intake.
openaire +1 more source